| Excerpt | Relevance | Reference |
|---|
| "The objective of this study was to determine comprehensive metabolic changes of caffeine in the serum of patients with parkinsonian disorders including Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) and to compare this with healthy control serum." | 7.96 | Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. ( Daida, K; Fujimaki, M; Funayama, M; Hatano, T; Hattori, N; Imamichi, Y; Ishiguro, Y; Ishikawa, KI; Li, Y; Mori, A; Nanmo, H; Nojiri, S; Oji, Y; Okuzumi, A; Saiki, S; Takeshige-Amano, H; Tsunemi, T; Ueno, SI, 2020) |
| "The objective of this study was to determine comprehensive metabolic changes of caffeine in the serum of patients with parkinsonian disorders including Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) and to compare this with healthy control serum." | 3.96 | Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. ( Daida, K; Fujimaki, M; Funayama, M; Hatano, T; Hattori, N; Imamichi, Y; Ishiguro, Y; Ishikawa, KI; Li, Y; Mori, A; Nanmo, H; Nojiri, S; Oji, Y; Okuzumi, A; Saiki, S; Takeshige-Amano, H; Tsunemi, T; Ueno, SI, 2020) |